Reference SummaryNielsen LL, Anticancer Res 1995 Mar-Apr;15(2):385-92
Title |
In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background. |
Authors |
Nielsen LL; Gurnani M; Catino JJ; Tyler RD |
Journal |
Anticancer Res |
Volume |
15 |
Issue |
2 |
Year |
1995 |
Pages |
385-92 |
Abstract |
Male wap-ras transgenic mice develop adenocarcinomas in salivary and/or mammary tissue by age 1 year. When the wap-ras transgene was bred into the FVB/N strain, males developed multiple mammary tumors between 1.5 and 3 mo. of age, but no salivary tumors. Crosses between ras/FVB mice and other strains produced moderate changes in mammary tumor onset and severity, but no salivary tumors. Histopathological analysis of 62 adenocarcinomas from 18 mice yielded: 14 tumors with areas of squamous metaplasia, many tumors with epithelium-lined cysts, few immune cells in tumors, and no lung metastases. Cyclophosphamide delayed tumor onset and inhibited the growth of established tumors. Our results suggest that wap-ras mice will be useful for studying ras-mediated tumor genetics and should be a good assay system for both preventative and curative anticancer therapies. |
Links |
J:46464 – MGI References 7763010 – National Library of Medicine/PubMed |
| |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma | Mammary gland |
98 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma | Mammary gland |
90 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma | Mammary gland |
100 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma | Mammary gland |
100 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma | Mammary gland |
100 |
||
| B6;SJL-Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma - adenosquamous | Mammary gland |
50 |
||
| FVB.B6SJLF1-Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma - adenosquamous | Mammary gland |
100 |
||
| FVB.B6SJLF1-Tg(Wap-HRAS)69Lln Chr YSJL | Mammary gland carcinoma - adenosquamous |
|
Mammary gland |
100 |
|
| B6;SJL-Tg(Wap-HRAS)69Lln Chr YSJL | Salivary gland - Submandibular adenocarcinoma | Salivary gland - Submandibular |
50 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Salivary gland - Submandibular adenocarcinoma | Salivary gland - Submandibular |
observed |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Salivary gland tumor | Salivary gland |
0 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Salivary gland tumor | Salivary gland |
0 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Salivary gland tumor | Salivary gland |
0 |
||
| STOCK Tg(Wap-HRAS)69Lln Chr YSJL | Salivary gland tumor | Salivary gland |
0 |
||
| FVB.B6SJLF1-Tg(Wap-HRAS)69Lln Chr YSJL | Salivary gland tumor | Salivary gland |
0 |